ReviewJournal of anesthesia2023
Dexmedetomidine as a cardioprotective drug: a narrative review.
Review in Journal of anesthesia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Anaesthetic Management Including Low-Dose Dexmedetomidine and Butorphanol in Dogs Undergoing ECG-Gated Cardiac Computed Tomography: A Retrospective Case Series.Veterinary sciences · 2026Article
- Retrospective Evaluation of Anesthetic-Analgesic Protocols in Cats with and Without Transient Myocardial Thickening Following Gonadectomy.Animals : an open access journal from MDPI · 2026Article
- Cardioprotective effects of right stellate ganglion block combined with dexmedetomidine in rats with atrial fibrillation-like atrial tachyarrhythmia.BMC cardiovascular disorders · 2026Article
- Effects of dexmedetomidine-remifentanil on hemodynamics and inflammatory responses in patients undergoing atrial fibrillation ablation.Open life sciences · 2026Article
- Analysis of conditioning with dexmedetomidine under endothelial dysfunction in isolated perfused hearts.Biomedical reports · 2025Article
- Article
- New insights in cardiovascular anesthesia: a dual focus on clinical practice and research.Journal of anesthesia · 2025Review
- Dexmedetomidine's Effect on Catecholamine and Inflammation in Reducing In-Hospital Adverse Events for Older Patients with STEMI Undergoing Primary PCI.Drug design, development and therapy · 2025Article
- Assessment of the Impact of Dexmedetomidine on Myocardial Injury in TAVI Patients: A Retrospective Cohort Study Utilizing PSM-DID.Therapeutics and clinical risk management · 2025Article
- Association of dexmedetomidine with short-term outcome in patients with cardiogenic shock: a retrospective propensity score-matched cohort study from MIMIC-IV.Frontiers in pharmacology · 2025Article
- Article
- Article
- Effect of acute normovolemic hemodilution in patients undergoing cardiac surgery with remimazolam anesthesia.Journal of anesthesia · 2024Article
- Dexmedetomidine administration is associated with improved outcomes in critically ill patients with acute myocardial infarction partly through its anti-inflammatory activity.Frontiers in pharmacology · 2024Article
- Pharmacokinetics study of atracurium, dexmedetomidine, midazolam and 1-hydroxymidazolam in patients undergoing acute aortic dissection surgery.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexmedetomidine (DEX), a highly selective alpha2-adrenoceptors agonist, is not only a sedative drug used during mechanical ventilation in the intensive care unit but also a cardio-protective drug against ischemia-reperfusion injury (IRI). Numerous preclinical in vivo and ex vivo studies, mostly evaluating the effect of DEX pretreatment in healthy rodents, have shown the efficacy of DEX in protecting the hearts from IRI. However, whether DEX can maintain its cardio-protective effect in hearts with comorbidities such as diabetes has not been fully elucidated. Multiple clinical trials have reported promising results, showing that pretreatment with DEX can attenuate cardiac damage in patients undergoing cardiac surgery. However, evidence of the post-treatment effects of DEX in clinical practice remains limited. In this narrative review, we summarize the previously reported evidence of DEX-induced cardio-protection against IRI and clarify the condition of the hearts and the timing of DEX administration that has not been tested. With further investigations evaluating these knowledge gaps, the use of DEX as a cardio-protective drug could be further facilitated in the management of patients undergoing cardiac surgery and might be considered in a broader area of clinical settings beyond cardiac surgery, including patients with acute myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.